Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is
- Est. revenue
- $10M–$20M
- Total raised
- $253M
- Latest round
- Grant
- Employees
- 150
Funding & revenue at Aspect Biosystems
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$10M–$20M
Modeled range, not company-reported
Total capital raised
$253M
26 known investors
Latest round
Grant · $56.8M
Apr 2026
Investors
Growth signals
How fast Aspect Biosystems is adding people, roles, and audience.
Employees
150
Reported band 51-200
LinkedIn followers
29.2K
+19.8% year over year
Headcount change
- MoM
- +0.7%
- +1 people
- QoQ
- +4.9%
- +7 people
- 6mo
- +5.6%
- +8 people
- YoY
- +22%
- +27 people
- 2yr
- +32.7%
- +37 people
Team composition
Where Aspect Biosystems concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research4429%
- Operations149%
- Engineering149%
- Business Development149%
- Quality Assurance107%
- Accounting53%
- Entrepreneurship43%
- Community And Social Services43%
By region
- Canada107
- British Columbia, Canada98
- Greater Vancouver Metropolitan Area96
- Vancouver, BC78
- United States27
- California, United States22
Inside Aspect Biosystems
What the business focuses on, where it operates, and how employees rate it.
Specialties
Categories
Markets
Competitors
Companies in the same market as Aspect Biosystems.
Aspect Biosystems in the news
Recent coverage picked up alongside the firmographic refresh.
- Regenerative Medicine Market worth $62.69 billion by 2031 - Exclusive Report by MarketsandMarkets™
Oct 2026
- Stem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research
Sep 2026
- Anti-Aging Drugs Market Poised for US$ 102.5 Bn Valuation by 2031, Growing at 6.25% CAGR, New Report by Wissen Research
Sep 2026
- Has Canada’s biotech moment finally arrived?
Aug 2026
- From UBC lab to $2.6-billion deal: Inside Vancouver’s Aspect Biosystems and its quest to transform diabetes treatment
Jul 2026
- From UBC partnerships to a biotech boom
Jun 2026
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed November 11, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Aspect Biosystems, you can claim this page to manage and enhance it.